Screening MPL515 mutations from 286 cases of essential thrombocythemia and primary myelofibrosis
10.3760/cma.j.issn.1009-9158.2012.07.012
- VernacularTitle:原发性血小板增多症及原发性骨髓纤维化患者MPL515突变的筛查
- Author:
Xiao XU
;
Xinju ZHANG
;
Zhiyuan WU
;
Xiaoping XU
;
Bobin CHEN
;
Tingting HU
;
Yuming CHEN
;
Ming GUAN
- Publication Type:Journal Article
- Keywords:
Thrombocytosis;
Myelofibrosis;
Receptors,thrombopoietin;
Janus kinase 2;
Mutation;
Polymerase chain reaction
- From:
Chinese Journal of Laboratory Medicine
2012;35(7):634-638
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo establish a simple and sensitive method to detect MPL515 mutations in peripheral blood of ET and PMF patients,and investigate the frequencies of the MPL515 and JAK2V617F mutations in Chinese patients.MethodsTotallv 261 patients of ET and 25 PMF cases were collected from Huashan Hospital of Fudan University and DNA samples were isolated from peripheral blood of these cases.SYBR GreenⅠreal-time PCR was used to detect JAK2V617F mutation.Taqman probe was designed to be specific for the three types of mutations ( MPl515wt,MPLW515L and MPIW515K).Real-time PCR was used to detect MPL515 mutations.Tbe results were confirmed by sequencing after T-A cloning.Results Among 261 ET patients,119 cases (45.6％ ) were identified as JAK2V617F mutation carriers and 7 cases (2.7％ ) were detected to be MPl515 mutation carriers,including 5 cases with MPLW515L,1 case with MPLW515K and 1 ease with MPLW515L + K.Additionally 10 cases with JAK2V617F(40.0％ ) and 3 cases with MPL515 ( 12.0％ ) were screened out in 25 PMF patients,including 1 case with MPLW515L and 2 cases with MPLW515L + K.One ET patient was found to harbor concurrent JAK2V617F and MPL515 mutations.ConclusionJAK2V617F mutation is the major molecular marker of ET and PMF,meanwhile MPL515 mutation is important and useful complement.
